- Home
- VTT
overview - Solutions
and services- Services by customer sector
- Service offering
- Research and
technology- Technology focus areas
- Other
- References
and results - News and
events - Publications
- Careers
- Contact
information
Business from technology
Customer service:
info@vtt.fi | tel. 020 722 7070
Search
By combining different technologies,
VTT makes it possible to diagnose
brain diseases earlier.
VTT is the leading research center in Northern Europe and
business enabler exploiting science, cross functional and
sustainable, leading edge technologies.
VTT biosignal competence helps improve patient critical care
VTT biosignal know-how is utilised in different health care applications. One specific field is brain monitoring in critical care in intensive care units and operating rooms. Biosignals can help to detect critical events in the patients’ state that require immediate attention, such as epileptic seizures, which would otherwise go unnoticed and could be life-threatening.
VTT introduces new solutions for the early detection of Alzheimer's disease
Alzheimer's disease will be one of the major health challenges of the next few decades. Combined with the new drugs under development and other forms of treatment, a successful early diagnosis can delay a patient's need for hospital care, reduce suffering and lower the costs incurred by society. Read more about the range of solutions VTT has developed for the diagnosis of the disease.
VTT manufactured sensor components help localizing brain function disorders
Magnetoencephalography (MEG) is a technique used in the functional brain mapping. It enables various diagnostic operations, such as localizing the source of epilepsy in the cerebral cortex. Finnish company Elekta Neuromag, the market leader in its field, uses magnetic field sensors developed and manufactured by VTT in its MEG devices.